Urological cancer. The benefits of intermittent androgen-deprivation therapy
- PMID: 23165125
- DOI: 10.1038/nrclinonc.2012.201
Urological cancer. The benefits of intermittent androgen-deprivation therapy
Abstract
The large randomized study by Crook et al. demonstrated that intermittent administration of androgen deprivation therapy should be considered the standard of care when patients with moderate and well-differentiated localized prostate cancer are treated for rising PSA levels after definitive radiotherapy.
Comment on
-
Intermittent androgen suppression for rising PSA level after radiotherapy.N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. N Engl J Med. 2012. PMID: 22931259 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous